Related Experiment Video
Updated: Dec 31, 2025
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Prostaglandin E2 as a therapeutic target in bladder cancer: From basic science to clinical trials
Benjamin L Woolbright1, Carol C Pilbeam2, John A Taylor1
1Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.
Abstract:
Bladder cancer (BCa) is a common solid tumor marked by high rates of recurrence, especially in non-muscle invasive disease. Prostaglandin E2 (PGE2) is a ubiquitously present lipid mediator responsible for numerous physiological actions. Inhibition of cyclooxygenase (COX) enzymes by the non-steroidal anti-inflammatory (NSAID) class of drugs results in reduced PGE2 levels. NSAID usage has been associated with reductions in cancers such as BCa. Clinical trials using NSAIDs to prevent recurrence have had mixed results, but largely converge on issues with cardiotoxicity. The purpose of this review is to understand the basic science behind how and why inhibitors of PGE2 may be effective against BCa, and to explore alternate therapeutic modalities for addressing the role of PGE2 without the associated cardiotoxicity. We will address the role of PGE2 in a diverse array of cancer-related functions including stemness, immunosuppression, proliferation, cellular signaling and more.
Insights
Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce bladder cancer (BCa) recurrence by inhibiting prostaglandin E2 (PGE2). This review explores PGE2
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Bladder cancer (BCa) frequently recurs, particularly in non-muscle invasive stages.
- Prostaglandin E2 (PGE2), a lipid mediator, influences numerous physiological processes.
- Non-steroidal anti-inflammatory drugs (NSAIDs) reduce PGE2 levels by inhibiting cyclooxygenase (COX) enzymes.
Purpose of the Study:
- To elucidate the fundamental mechanisms by which PGE2 inhibition may combat BCa.
- To investigate alternative therapeutic strategies targeting PGE2 pathways, mitigating cardiotoxicity risks associated with NSAIDs.
Main Methods:
- Review of existing scientific literature on PGE2, NSAIDs, and bladder cancer.
- Analysis of PGE2's role in cancer stemness, immune suppression, proliferation, and signaling pathways.
Main Results:
- NSAID use is linked to reduced incidence of certain cancers, including BCa.
- Clinical trials on NSAIDs for BCa recurrence prevention show mixed outcomes, often complicated by cardiotoxicity.
- PGE2 is implicated in various cancer-promoting functions.
Conclusions:
- Understanding PGE2's multifaceted role in BCa is crucial for developing effective therapies.
- Exploring novel therapeutic modalities that target PGE2 without the adverse effects of traditional NSAIDs is warranted.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle